handouts presentation · • discrepancy between animal and human models of alloimmunization •...
Post on 04-Jul-2020
2 Views
Preview:
TRANSCRIPT
PresentationHandouts
(9202-S)
Tibor Greenwalt Memorial Award and
Lectureship: They Are Not Just Little
Adults
October 7, 2012 9:15 AM - 10:00 AM
Event Faculty List
Event Title: 9202-S: Tibor Greenwalt Memorial Award and Lectureship: They Are Not Just Little Adults
Event Date: Sunday, October 7, 2012 Event Time: 9:15 AM to 10:00 AM
Director/Moderator Karina Yazdanbakhsh, PhD Associate Member New York Blood Center KYazdanbakhsh@NYBloodCenter.org Disclosures: No
Award Recipient/Speaker Naomi Luban, MD Chief , Division of Laboratory Medicine Children's Hospital NLUBAN@CNMC.ORG Disclosures: No
1
11
Naomi L. C. Luban, MDChief, Division of Laboratory Medicine
Director, Transfusion Medicine / The Edward J. Miller Donor Center Vice Chair for Academic Affairs, Department of Pediatrics
Children's National Medical CenterProfessor, Pediatrics and Pathology
George Washington University School of Medicine and Health Science
Tibor Greenwalt Memorial Award and Lectureship
October, 2012
They Are Not Just Small Adults
22
Tibor Greenwalt as Mentor and Advisor
33
Background and Training: Threads of a Career
Best friend with ALL, treated by Dr. Sidney Farber at Boston Children’s
Parents who supported science and mathematics
NSF summer high school experience in regenerative biology at Brandeis
College summers in cancer biology lab at Tufts
First rotation in medical school in pediatrics at Mt. Sinai
Fellowship at Cornell / Sloan Kettering / Rockefeller
Sidney Farber Abraham Jacobi Alexander Wiener
Karl Landsteiner Hans Popper
Sanford Leiken Margaret Hilgartner Anthony Cerami
2
44
Reflections on What Constitutes the Discipline
Blood banking: the collection, processing and storage of peripheral blood, bone marrow and hematopoietic stem cells (HSCs)
Clinical transfusion medicine: transfusion / transplantation of blood / blood products, HSC and progenitor blood cells
Transfusion biology: cellular and molecular biology of blood cells, immunopathology of transfusion, engineering of stem and immunocompetent cells
55
Infants and Children Are Not Just Small Adults
Unique pathophysiology Progress from fetus to adolescent Are often born too soon Suffer unique complications Live long lives Are our future
66
Infants and Children Are Not Just Small Adults: Pathophysiology
Specific to Developmental Hematology• Adaptive responses to anemia and thrombocytopenia• Coagulation and anticoagulation proteins• Humoral and cellular immunity• Glucuronidation and other protein-bound excretory
pathwaysSpecific to Size
• Total blood and plasma volumes• Pharmacokinetics of volume distribution and excretion
Specific to Neonatal Physiology• Neurodevelopmental immaturity • Permeability of blood / brain and blood / testis barriers• Response to toxicants, additives and medications
3
77
Infants and Children Are Not Just Small Adults: Real Life Examples
Average volume RBC unit = 250 mL Blood volume of premature infant of 500 gm at 100 mL/kg = 50 mL Usual transfusion volume at 10 mL/kg = 5 mL
88
Andrews M. Developmental Hemostasis: Relevance to thromboembolic complications in pediatric patients. Thromb Haemost. 1995;74 (1 Suppl):415-425
Reverdiau-Moalic P, et al. Evolution of blood coagulation activators and inhibitors in the healthy human fetus. Blood. 1996;88:900-906
Fetuses, Infants and Children Are Not Just Small Adults: Real Life Examples
99
Career Goals: Apply Principles and Practices of Pediatrics to Transfusion Medicine
To develop a program of clinical, epidemiological and translational research, education and service directed toward the safe, efficacious delivery of blood, blood products and hematopoietic stem cells to vulnerable populations, recognizing their uniqueness.
4
1010
Hemolytic Anemia, Coagulation and Stem Cell Biology
Established: • Focus on congenital hemolytic anemia,
coagulation and transplantation biology• Opportunity over time to serve NIH, FDA
and CDC in DSMB’s, SEPs and review panels
Challenges: • Maximizing therapy for iron related organ
toxicity• Improving HSC transplantation outcomes,
especially Graft vs. Host Disease• RBC allo- / autoantibody development
LIC 24.7 mg/gm
1111
Transfusion-related Immune Modulation in Hemophilia
Established: • Commitment to dissecting adverse
immunological consequences of transfusion• Involvement as regional Hemophilia Treatment
Center director and participant in clinical trials and epidemiological outcome studies in hemophilia
• Plasma derived hemophilia products replaced by recombinant products, obviating concern for HIV / HCV / Parvo
Challenges:• Inhibitor development and Immune Tolerance
Induction protocols• Initiation of prophylaxis to prevent joint disease• Gene therapy and long acting products
1212
Adapting Transfusion Practice to Meet Needs of Infants
Established:• Challenging bag and device manufacturers to recognize
the transfused neonate as an “underserved” population• Involvement with AABB: Technical Manual, SSCC,
Pediatric Hemotherapy Committee and the Board• Collaborations with Drs. Strauss, Sacher, Roseff and
PisciottoChallenges:• Guidelines and criteria for transfusion in neonates still
unsettled• New anticoagulant / storage solutions and devices require
neonatal / pediatric considerations• Importance of age of blood still in flux
R. Strauss R. Sacher S. Roseff P. Pisciotto
5
1313
Transfusion Transmitted Infections in Pediatric Patients
Established:• Ongoing partnership with Dr. Harvey Alter and DTM / NIH
colleagues• Use of molecular methods to identify transfusion transmitted
diseasesChallenges:• CMV and Parvo B19 “safe” product selection for fetus / neonate
still questioned • New and emerging infectious and other risks continue• Paucity of longitudinal risk assessment for neonates for drugs,
devices, and “off label” processes
Supported by: 5R01HL067229 and HHSF223200910021C through FDA
1414
Immune Dysregulation Results in RBC Allo-and Autoantibody Development in SCD
Established:• Molecular phenotyping focus and investigations on
molecular basis of alloimmunization• Consultant roles in SCD transfusion studies: CSSCD,
STOP I and II; SWiTCH and TWiTCHChallenges:• Discrepancy between animal and human models of
alloimmunization• Responder versus non-responder phenotype still not
identifiable• Computerization of molecular donor/ recipient matching
ABO/Rh
Type
RBC transfused
Hgb S pattern
Serological Rh CE phenotype Molecular Rh CE phenotype
C c E e C c E e
B Neg 8 SS (SF) Pos Pos Neg Pos Neg Pos Neg Pos
Known Antibodies
Rh Variant
Extended Phenotype
Anti-"e" like (hrS/hrB)
r's + "e" variant
K-, k+, Fya-, Fyb-, Jka+, Jkb+, M+, N-, S-, s+ / Lea-, Leb-, P1+
1515
Transfusion-associated Graft vs. Host Disease: Applying Transplantation and Radiation Biology
Concepts to Blood IrradiationEstablished:• Consideration of dosimetry and use of LDA to assess irradiation
effect• Contribution to FDA regulation
“The dose of irradiation delivered should be 2500 cGy targeted to the central portion of the container and the minimum dose should be 1500 cGy at any other point.”
http://www.fda.gov/cber/guidelines.htm• Expanded indications to include premature infant and othersChallenges:• Immunobiology of the premature / neonate not well studied • Cause of adverse effect of irradiation on RBC and storage lesion• Product availability and advisability of universal irradiation or
equivalent process for all patients
6
1616
Increasing Blood Donors with a Commitment to Specific Patient Populations
Established:• Efficacy of focused donor recruitment: “Buddy” Programs• Self sufficiency of blood / blood products unique to needs of
selected patientsChallenges:• Indications for prophylactic transfusion for SCD will increase
need for antigen phenotyped products • Future of molecular phenotyping• Effect of toxicants, drugs and metals (Pb) in donor blood• Focus on “age of blood” and inventory management
1717
In Learning You Will Teach, And In Teaching You Will Learn … Phil Collins
1818
Importance of Research in Infants and Children: Why Are They a Unique Population and Not Just Small Adults
They have diseases adults don’t haveRh Hemolytic Disease, Necrotizing Enterocolitisand Neonatal AlloimmuneThrombocytopenia
They have diseases adults have, but with different pathophysiology
- Hypertension in Complex Congenital Heart Disease- Stroke in Sickle Cell Disease
They have access to off-label use of drugs which improve outcome, but can be taken away due to adult complications
Drug Research and ChildrenMost drugs prescribed for children have not been tested in children.
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143455.htm
7
1919
Small sample size and small subjects make collaboration vital
- multiple illnesses- epigenetic confounders- risk-benefit, a parental concern
“Hand-me-down” medications often not optimal
Developmental origins of disease can be identified
Significant prevention opportunities
Challenges and Opportunities in Pediatric Research
2020
How Can We Improve the Research We Perform in Kids?
Careful observational and epidemiologic research
Elegant basic science research
Development of animal models
Careful clinical “phenotyping”
Quality investigator-initiated clinical trials
Collaboration between epidemiologists, basic scientists, and clinicians
Technical advances which focus on infants and children
20
2121
The Future of Pediatric Research: Leveling the Playing Field
Research networks will broaden patient availability
“No More Hand-Me-Downs”: Children and Clinical Studies campaign (http://www.nhlbi.nih.gov/childrenandclinicalstudies/index.php)
Pediatric devices: incentivizing small business through SBIR grants
Prevention: evidence-based pediatric guidelines
8
2222
The Future of Pediatric Research in Transfusion Medicine: Federally Funded Clinical Trials and Studies Relevant to
Transfusion Medicine
Hemophilia RESIST:Plasma derived vs. monoclonal product
SIPPET: Inhibitors in toddlers with hemophilia
Blood transfusionTransfusion of Preemies (TOP) TrialIOWA Program Project in Neonatal TransfusionTT: CMV Observational Birth Cohort StudyTransfusion Medicine / Hemostasis Clinical Trials Network: Pediatric Subgroup and Pedi-PLADORed Cell Storage duration Study (RECESS)
Sickle Cell DiseaseTWiTCH: TCD With Transfusion Changing to HydroxyureaSITT: Silent Cerebral Infarct Transfusion Trial
At this meeting ARIPI: Age of Red Blood Cells In Premature Infants: P3-030A
2323
Mentorship of Junior Faculty: Contributing to New Knowledge
Molecular characterization of RBC alloimmunization in SCD
Application of RBC molecular phenotyping andD variants
Cytochrome C oxidase and platelet storage defects
Coagulopathy of neonatal hypothermia usingThromboelastogram (TEG)
Di(2-Ethylhexl)phthalate and Bisphenol A Exposure inpediatric cardiac surgery
Expression patterns of fetal hemoglobin and reticulocytephenotype in children with SCD and during HSCT
Genomics and metabolomics of necrotizing enterocolitis
Inflammatory markers in Extracorporeal Photopheresis
Longitudinal assessment of transfusion-transmitteddiseases
Supported by: 1T32HL110841-01 and UL1RR031988 / UL1TR000075
2424
With Thanks to All Who Have Made Our Work and This Award Possible
9
2525
And to Children of the District of Columbia and the NIH’s Science Education Partnership Award: “Being Me”
http://www.childrensnational.org/beingme/
Our Next Generation of Scientists
Funded by: 8R25OD010969-04
2626
With Gratitude to My Family: “Always have someone to love, something to do and something to look forward to”
2727
And to Duffy Who Always Made Us Smile
10
2828
“To laugh often and much; to win the respect of intelligent people and the attention of children…to leave the world a better place…to know one life has breathed easier because you have lived. This is to have succeeded.”
Ralph Waldo Emerson
And First Do No Harm
top related